Currently out of the existing stock ratings of Julian Harrison, 29 are a BUY (93.55%), 2 are a HOLD (6.45%).

Julian Harrison

Work Performance Price Targets & Ratings Chart

Analyst Julian Harrison works at BTIG with a stock forecast success ratio of 46.97% fulfilled within 269.36 days on average.

Julian Harrison’s has documented 58 price targets and ratings displayed on 11 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CBAY, Cymabay Therapeu at 13-Feb-2024.

Wall Street Analyst Julian Harrison

Analyst best performing recommendations are on AVTE (AEROVATE THERAPEUTICS).
The best stock recommendation documented was for AVTE (AEROVATE THERAPEUTICS) at 12/6/2022. The price target of $27 was fulfilled within 6 days with a profit of $8.97 (49.75%) receiving and performance score of 82.92.

Average potential price target upside

PTGX Protagonist Therapeutics LQDA Liquidia Technologies AVTE Aerovate Therapeutics RXDX Prometheus Biosciences KROS Keros Therapeutics  ACRS Aclaris Therapeutics AXLA Axcella Health VKTX Viking Therapeutics MORF Morphic CBAY Cymabay Therapeu MLTX MoonLake Immunotherapeutics

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

37

$8.52 (29.92%)

35

3 months 21 days ago

2/5 (40%)

$20.35 (122.22%)

136

Buy

38

$9.52 (33.43%)

38

4 months 14 days ago

2/9 (22.22%)

$21.62 (131.99%)

514

Buy

35

$6.52 (22.89%)

35

7 months 21 days ago

0/9 (0%)

$12.69 (56.88%)

Buy

41

$12.52 (43.96%)

45

7 months 21 days ago

0/3 (0%)

$18.69 (83.77%)

Buy

40

$23.32 (139.81%)

60

8 months 30 days ago

1/3 (33.33%)

$16.44 (62.17%)

216

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Julian Harrison is most bullish on?

Potential upside of $0 has been obtained for CBAY (CYMABAY THERAPEU)

Which stock is Julian Harrison is most reserved on?

Potential downside of -$0 has been obtained for ACRS (ACLARIS THERAPEUTICS)

What Year was the first public recommendation made by Julian Harrison?

On 2020

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?